| Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial M Valgimigli, G Campo, M Monti, P Vranckx, G Percoco, C Tumscitz, ... Circulation 125 (16), 2015-2026, 2012 | 817 | 2012 |
| Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy … P Vranckx, M Valgimigli, P Jüni, C Hamm, PG Steg, D Heg, GA van Es, ... The Lancet 392 (10151), 940-949, 2018 | 689 | 2018 |
| Two-year outcomes after first-or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre … M Valgimigli, M Tebaldi, M Borghesi, P Vranckx, G Campo, C Tumscitz, ... JACC: Cardiovascular interventions 7 (1), 20-28, 2014 | 159 | 2014 |
| Ticagrelor alone versus dual antiplatelet therapy from 1 month after drug-eluting coronary stenting A Franzone, E McFadden, S Leonardi, R Piccolo, P Vranckx, PW Serruys, ... Journal of the American College of Cardiology 74 (18), 2223-2234, 2019 | 122 | 2019 |
| Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the … PW Serruys, K Takahashi, P Chichareon, N Kogame, M Tomaniak, ... European heart journal 40 (31), 2595-2604, 2019 | 99 | 2019 |
| Randomized comparison of 6-versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary … M Valgimigli, G Campo, G Percoco, M Monti, F Ferrari, C Tumscitz, A Zuffi, ... American Heart Journal 160 (5), 804-811, 2010 | 91 | 2010 |
| Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study I. Short-versus long-term duration of dual-antiplatelet therapy after coronary … M Valgimigli, G Campo, M Monti, P Vranckx, G Percoco, C Tumscitz, ... Circulation 125 (16), 2015-2026, 2012 | 81 | 2012 |
| Short-versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After … G Campo, M Tebaldi, P Vranckx, S Biscaglia, C Tumscitz, R Ferrari, ... Journal of the American College of Cardiology 63 (6), 506-512, 2014 | 78 | 2014 |
| Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey M Valgimigli, F Costa, R Byrne, M Haude, A Baumbach, S Windecker, ... EuroIntervention: journal of EuroPCR in collaboration with the Working Group …, 2015 | 61 | 2015 |
| Acute myocardial infarction and large coronary thrombosis in a patient with COVID‐19 D Tedeschi, A Rizzi, S Biscaglia, C Tumscitz Catheterization and Cardiovascular Interventions 97 (2), 272-277, 2021 | 58 | 2021 |
| Use of the dual-antiplatelet therapy score to guide treatment duration after percutaneous coronary intervention R Piccolo, G Gargiulo, A Franzone, A Santucci, S Ariotti, A Baldo, ... Annals of internal medicine 167 (1), 17-25, 2017 | 55 | 2017 |
| Fractional Flow Reserve Evaluation and Chronic Kidney Disease: Analysis From a Multicenter I talian Registry (the FREAK Study) M Tebaldi, S Biscaglia, M Fineschi, A Manari, M Menozzi, GG Secco, ... Catheterization and Cardiovascular Interventions 88 (4), 555-562, 2016 | 53 | 2016 |
| Angio-based index of microcirculatory resistance for the assessment of the coronary resistance: a proof of concept study M Tebaldi, S Biscaglia, D Di Girolamo, A Erriquez, C Penzo, C Tumscitz, ... Journal of Interventional Cardiology 2020, 2020 | 52 | 2020 |
| Impact of sex on comparative outcomes of radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: data from the randomized MATRIX … G Gargiulo, S Ariotti, P Vranckx, S Leonardi, E Frigoli, N Ciociano, ... JACC: Cardiovascular Interventions 11 (1), 36-50, 2018 | 49 | 2018 |
| PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY F Gragnano, D Heg, A Franzone, EP McFadden, S Leonardi, R Piccolo, ... European Heart Journal-Cardiovascular Pharmacotherapy 8 (1), 28-38, 2022 | 46 | 2022 |
| Occurrence, causes, and outcome after switching from ticagrelor to clopidogrel in a real-life scenario: data from a prospective registry S Biscaglia, G Campo, R Pavasini, M Tebaldi, C Tumscitz, R Ferrari Platelets 27 (5), 484-487, 2016 | 46 | 2016 |
| Role of the tricuspid regurgitation after mitraclip and transcatheter aortic valve implantation: a systematic review and meta-analysis R Pavasini, S Ruggerini, J Grapsa, S Biscaglia, C Tumscitz, M Serenelli, ... European Heart Journal-Cardiovascular Imaging 19 (6), 654-659, 2018 | 37 | 2018 |
| Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design M Valgimigli, G Campo, N de Cesare, P Vranckx, M Hamon, DJ Angiolillo, ... Cardiovascular drugs and therapy 22, 313-320, 2008 | 37 | 2008 |
| Complete or culprit-only PCI in older patients with myocardial infarction S Biscaglia, V Guiducci, J Escaned, R Moreno, V Lanzilotti, A Santarelli, ... New England Journal of Medicine 389 (10), 889-898, 2023 | 36 | 2023 |
| Acute myocardial infarction caused by amphetamines: a case report and review of the literature GM Costa, C Pizzi, B Bresciani, C Tumscitz, M Gentile, R Bugiardini Italian Heart Journal 2, 478-480, 2001 | 34 | 2001 |
Gianluca CampoU.O. Cardiologia, Azienda Ospedaliera di FerraraVerified email at unife.it
